Navigation Links
BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
Date:12/9/2011

ocess; the ability of Pfizer, Inc. to achieve its objectives for XIAPEX® in Europe; the ability of Asahi Kasei Pharma Corporation to achieve its objectives for XIAFLEX in Japan; the success of the Phase III trials for XIAFLEX for the treatment of Peyronie's disease; our ability to conduct clinical trials or development work for additional indications, which may be limited by our development and license agreement, as amended August 31, 2011, with Auxilium; the outcome of future clinical trials for additional indications including frozen shoulder, cellulite, human lipoma and canine lipoma, all of which will determine the amount of milestone, royalty and sublicense income we may receive; the potential of XIAFLEX to be used in additional indications; the receipt of any applicable milestone payments from Auxilium; and other risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2010 and in other reports we file from time to time with the Securities and Exchange Commission.  All forward-looking statements included in this release are made as of the date hereof, and we assume no obligation to update these forward-looking statements.

    


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 The global oligonucleotide synthesis ... 2019 from $1,070.7 million in 2014, growing at ... The global oligonucleotide synthesis market is categorized on ... users, and geography. The synthesized oligonucleotides segment is ... the oligonucleotide synthesis market during the forecast period, ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
... The Quigley,Corporation (Nasdaq: QGLY ) today issued an ... Diabetic Peripheral Neuropathy by its wholly owned,subsidiary, Quigley Pharma, ... noted that over 100 subjects have been,enrolled, 52 subjects ... for the Phase IIB study designed to evaluate the ...
... VALLEY COTTAGE, New York, September 11 XTL,Biopharmaceuticals Ltd. ... hold a,conference call today, September 11, 2007, at 8:30 ... Bicifadine for the treatment of diabetic,neuropathic pain that was ... Bentsur, XTL,s Chief Executive Officer.,Participating on the call will ...
... DIEGO, Sept. 10 SGX Pharmaceuticals, Inc.,(Nasdaq: ... license and collaboration,agreement with Novartis focused on the ... of both first line and drug resistant,Chronic Myelogenous ... Novartis are progressing a number of,potential drug candidates, ...
Cached Biology Technology:Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 3Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2SGX Provides Update on BCR-ABL Collaboration 2SGX Provides Update on BCR-ABL Collaboration 3
(Date:9/1/2014)... every child in the U.S. undergoes a battery of ... sickle cell disease. Thousands of children born in the ... and die from the disease each year. , ... least some of those deaths. , A Post-Doctoral ... lab of George Whitesides, the Woodford L. and Ann ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... life without light. They emit echolocation sounds and use the ... or prey. In their brains, they have a spatial map ... at Technische Universitt Mnchen (TUM) has shown for the first ... , Closer objects appear larger , When ... number of activated neurons in its brain increases. As a ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... , New research into the Earth,s paleoclimate history by ... Hansen suggests the potential for rapid climate changes this ... global warming is not abated. By looking at ... Hansen sought insight into a fundamental question raised by ...
... Gil and Rongchao Jin have successfully used NMR ... which could advance the development and use of ... Their approach offers a significant advantage over routine ... determine whether the nanoparticles exist in a both ...
... York, NYDecember 7, 2011Thanks to a new study ... able to diagnose in their offices non-periodic arrhythmiasnoninvasively ... arrhythmias include atrial and ventricular fibrillation, which are ... in some cases be life-threatening. Using ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 2Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 3New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat 2
Sphingosine 1-phosphate receptor Edg-1...
VAP-1 (S-13)...
Human SPARC-like 1 Biotinylated Affinity Purified PAb...
... at the 3, 3', 4, and 4' ... an internal standard for the quantification of ... spectrometry. PGE2 is one of the primary ... of the most widely investigated prostaglandins. Its ...
Biology Products: